SMAD4 and neoplasm: This study showed that, upon up-regulation of HLA class I and APM expression through IFN-γ treatment of CSCs/CICs, T cells could specifically recognize a neoantigen, SMAD4, generated by a non-synonymous mutation bearing stem-like cells and bulk tumor cells [65].